Evidence map›Paper›PMID 28490022›Full record

Trial reportPsychotherapy and psychosomatics2017

Concurrent Treatment with Prolonged Exposure for Co-Occurring Full or Subthreshold Posttraumatic Stress Disorder and Substance Use Disorders: A Randomized Clinical Trial.

Lesia M Ruglass, Teresa Lopez-Castro, Santiago Papini, Therese Killeen, Sudie E Back, Denise A Hien

Registry-linked trialOpen access · bronzeAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Psychotherapy and psychosomatics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04760418 (Evaluating the Impact of Trauma, Trauma-Focused Therapy Services, and COVID-19 Among Patients in the University of Kentucky SMART Clinic), which is not on this map. Cited by 62 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
62citing papers in PubMed, 6 pooled it
9.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04760418 nacompletednot on this mapstarted 2021, after this paper: background citation

Evaluating the Impact of Trauma, Trauma-Focused Therapy Services, and COVID-19 Among Patients in the University of Kentucky SMART Clinic

TypeinterventionalSponsorChristal L BadourRan2021 to 2022Enrolled21ConditionsPTSD, Opioid-use Disorder, Substance Use DisordersArmsConcurrent Treatment of PTSD and Substance Use Disorders Using Prolonged Exposure (COPE)
3 · Its place in the literature

Who cites it

62 citing papers in PubMed, 6 syntheses or guidelines pooled it, 95 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

2 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Lesia M RuglassThe City College of New York of CUNY, New York, NY, USA.
Teresa Lopez-Castro
Santiago Papini
Therese Killeen
Sudie E Back
Denise A Hien
City College of New York · USMedical University of South Carolina · USColumbia University · USThe University of Texas at Austin · US

Funding

A Randomized Trial of Concurrent Treatment for PTSD and Substance DependenceR01DA023187 · NIDA · CITY COLLEGE OF NEW YORK · PI HIEN, DENISE AIMEE · 2008 to 2011
$2.4M
NIDA NIH HHS R01 DA023187
6 · The paper itself

Abstract

backgroundTo test whether an integrated prolonged exposure (PE) approach could address posttraumatic stress disorder (PTSD) symptoms effectively in individuals with co-occurring substance use disorders (SUD), we compared concurrent treatment of PTSD and SUD using PE (COPE) to relapse prevention therapy (RPT) for SUD and an active monitoring control group (AMCG).

methodsWe conducted a randomized 12-week trial with participants (n = 110; 64% males; 59% African Americans) who met Diagnostic and Statistical Manual of Mental Disorders, fourth edition, text revision criteria for full or subthreshold PTSD and SUD. Participants were randomly assigned to COPE (n = 39), RPT (n = 43), or AMCG (n = 28).

resultsAt the end-of-treatment, COPE and RPT demonstrated greater reduction in PTSD symptom severity relative to AMCG (COPE-AMCG = -34.06, p < 0.001; RPT-AMCG = -22.58, p = 0.002). Although the difference between COPE and RPT was not significant in the complete sample, the subset of participants with full (vs. subthreshold) PTSD demonstrated significantly greater reduction of PTSD severity in COPE relative to RPT. Both treatments were superior to AMCG in reducing the days of primary substance use (COPE-AMCG = -0.97, p = 0.01; RPT-AMCG = -2.07, p < 0.001). Relative to COPE, RPT showed significantly more improvement in SUD outcome at end-of-treatment (RPT-COPE = -1.10, p = 0.047). At 3-month follow-up, COPE and RPT maintained their treatment gains and were not significantly different in PTSD severity or days of primary substance use.

conclusionCOPE and RPT reduced PTSD and SUD severity in participants with PTSD + SUD. Findings suggest that among those with full PTSD, COPE improves PTSD symptoms more than a SUD-only treatment. The use of PE for PTSD was associated with significant decreases in PTSD symptoms without worsening of substance use.

Indexed as

ComorbidityAdultFemaleHumansMaleMiddle AgedNew YorkPsychiatric Status Rating ScalesSecondary PreventionSeverity of Illness IndexStress Disorders, Post-TraumaticSubstance-Related DisordersTreatment OutcomeComorbidityIntegrated treatmentPosttraumatic stress disorderRandomized clinical trialSubstance use disorder

Identifiers

PMID28490022
PMCPMC5610572
OpenAlexW2612312268

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.